Drugs /

obi-821

Back to Drugs List

Overview

NCI Definition [1]:
A purified, natural saponin isolated from the soapbark tree Quillaja saponaria Molina with potential immunoadjuvant activity. When co-administered with a vaccine, OBI-821 may increase antibody and cytotoxic T-lymphocyte (CTL) responses against the vaccine's targeted antigen(s).

Clinical Trials

View Clinical Trials for obi-821

Obi-821 has been investigated in 4 clinical trials, of which 3 are open and 1 is closed. Of the trials investigating obi-821, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open).

ER Negative, ER No Expression, and Globo H are the most frequent biomarker inclusion criteria for obi-821 clinical trials.

Neuroblastoma, breast carcinoma, and colorectal carcinoma are the most common diseases being investigated in obi-821 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Obi-821
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Obi-821
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating obi-821 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
opt-821, immunological adjuvant opt-821, saponin-based immunoadjuvant obi-821, qs-21
NCIT ID [1]:
C91726

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.